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Abstract
Aims There is debate on whether the beneficial effect of implantable cardioverter-defibrillators (ICDs) is attenuated in pa-
tients with non-ischaemic cardiomyopathy (NICM). We assess whether any ICD benefit differs between patients with NICM
and those with ischaemic cardiomyopathy (ICM), using data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Frac-
tion (WARCEF) trial.
Methods and results We performed a post hoc analysis using WARCEF (N = 2293; ICM, n = 991 vs. NICM, n = 1302), where
participants received optimal medical treatment. We developed stratified propensity scores for having an ICD at baseline using
41 demographic and clinical variables and created 1:2 propensity-matched cohorts separately for ICM patients with ICD
(N = 223 with ICD; N = 446 matched) and NICM patients (N = 195 with ICD; N = 390 matched). We constructed a Cox propor-
tional hazards model to assess the effect of ICD status on mortality for patients with ICM and those with NICM and tested the
interaction between ICD status and aetiology of heart failure. During mean follow-up of 3.5 ± 1.8 years, 527 patients died. The
presence of ICD was associated with a lower risk of all-cause death among those with ICM (hazard ratio: 0.640; 95% confidence
interval: 0.448 to 0.915; P = 0.015) but not among those with NICM (hazard ratio: 0.984; 95% confidence interval: 0.641 to
1.509; P = 0.941). There was weak evidence of interaction between ICD status and the aetiology of heart failure (P = 0.131).
Conclusions The presence of ICD is associated with a survival benefit in patients with ICM but not in those with NICM.
Keywords Heart failure with reduced ejection fraction; Implantable cardioverter-defibrillator; Non-ischaemic cardiomyopathy;
Propensity score matching
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Introduction
The 2013 American College of Cardiology/American Heart
Association Guidelines for the Management of Heart Failure
(HF) and the 2016 European Society of Cardiology Guidelines
for the Diagnosis and Treatment of Acute and Chronic HF rec-
ommend implantable cardioverter-defibrillator (ICD) implan-
tation for prevention of death in patients with HF with
reduced ejection fraction.1,2 While there is considerable
evidence that ICDs prevent death in patients with ischaemic
cardiomyopathy (ICM),3,4 the evidence for patients with
non-ischaemic cardiomyopathy (NICM) is less robust.
The Defibrillators in Non-Ischaemic Cardiomyopathy Treat-
ment Evaluation (DEFINITE) trial5 did not show a significant
survival benefit for ICD, though there was a trend towards
mortality reduction. Similarly, although the Sudden Cardiac
Death in Heart Failure Trial (SCD-HeFT) demonstrated im-
proved mortality with ICD therapy for patients with cardio-
myopathy, the subgroup analysis for non-ischaemic patients
showed attenuated benefit.4 More recently, the Danish Study
to Assess the Efficacy of ICDs in Patients with Non-Ischaemic
Systolic Heart Failure on Mortality (DANISH) trial6 failed to
show a survival benefit for ICDs compared with optimal med-
ical therapy. However, updated meta-analyses7–11 continue
to suggest a survival benefit for ICD implantation among pa-
tients with NICM, a recommendation that is reflected in cur-
rent guidelines. For these reasons, there is considerable
interest in additional analyses of whether the impact of hav-
ing an ICD may differ depending on HF aetiology.12
The Warfarin versus Aspirin in Reduced Cardiac Ejection
Fraction (WARCEF) trial, a large randomized, clinical trial of
patients with HF with reduced ejection fraction that tested
the effect of warfarin vs. aspirin on death and stroke, pro-
vides an important opportunity to address this critical ques-
tion. We conducted an analysis using WARCEF data to
further elucidate the relation between ICD status and mortal-
ity for HF patients with ICM and NICM, using a propensity
score-based approach to limit confounding.
Methods
Study participants
The investigation conforms with the principles outlined in the
Declaration of Helsinki. Details of the WARCEF trial have been
published previously.13 A total of 2305 patients with left ven-
tricular ejection fraction ≤ 35% in sinus rhythm were ran-
domly assigned to warfarin (target international normalized
ratio 2.75, with an acceptable target range of 2.0 to 3.5) or
aspirin (325 mg/day). Left ventricular ejection fraction was
measured by radionuclide ventriculography, left ventriculog-
raphy, or quantitative echocardiography. Based on those
findings and patients’ past medical history, the aetiology of
HF was determined by clinical judgement of each local site.
Patients were enrolled at 168 centres in 11 countries be-
tween October 2002 and January 2010. The mean follow-up
time was 3.5 ± 1.8 years. Patients who had a clear indication
for warfarin or aspirin were not eligible. Additional eligibility
criteria were a modified Rankin score of 4 or less (on a scale
of 0 to 6, with higher scores indicating more severe disability)
and planned treatment with a beta-blocker, an angiotensin-
converting enzyme (ACE)-Inhibitor [or, if the side-effect
profile with ACE-Inhibitors was unacceptable, with an angio-
tensin II receptor blocker (ARB)], or hydralazine and nitrates.
Patients were ineligible if they had a condition that conferred
a high risk of cardiac embolism, such as atrial fibrillation, a
mechanical cardiac valve, endocarditis, or an intracardiac mo-
bile or pedunculated thrombus.
For this analysis, we excluded 12 enrolled patients because
of lack of data on either aetiology of HF or ICD status at base-
line (Figure 1). Information regarding indications for ICD, and
whether or not the patients received concurrent cardiac
resynchronization therapy (CRT), was not recorded in
WARCEF.
Assessment of outcomes
In the WARCEF trial, an independent endpoint adjudication
committee, whose members were unaware of the treatment
assignment, adjudicated major clinical outcomes. The com-
mittee adjudicated cause of death based on the standardized
narrative reports on patients’ status preceding death. If appli-
cable and available, discharge summary; detailed report by
physician, nursing staff, or family; autopsy report; death cer-
tificate; and other materials were considered as materials for
adjudication. Post-mortem ICD interrogation was not always
available but was considered in adjudication process if it
was available. In the current analysis, the primary outcome
was all-cause death, and the secondary outcomes were car-
diovascular death and sudden death. Deaths were adjudi-
cated as having a cardiovascular or non-cardiovascular
cause, and cardiovascular deaths were then adjudicated as
sudden or other types. The adjudication was not blinded to
ICD status.
Statistical analysis
Baseline characteristics were assessed by ICD status and for
ICM and NICM groups separately. Continuous variables are
presented as mean ± SD and categorical variables as frequen-
cies and percentages. They were considered balanced if the
standardized bias was less than 0.25.14 This is the difference
in means (for continuous variables) or proportions (for each
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category of a categorical variable) divided by the pooled stan-
dard deviation.
A propensity score matching approach was used to adjust
for potential confounding in the comparison of patients
who had or did not have implanted ICDs at randomiza-
tion.15,16 The goal is to assess whether any ICD benefit differs
between NICM and ICM patients, rather than to measure ICD
benefit in the overall population. We therefore match ICD to
non-ICD patients within the NICM stratum and, separately,
ICD to non-ICD patients within the ICM stratum.The propen-
sity score model initially included 41 patient covariates, NICM
vs. ICM status, and the interaction of this status with each of
the covariates in a logistic regression model. To avoid
overfitting, the final model included the subset of predictor
variables that optimized the Akaike information criterion in
a stepwise procedure.
We implemented the matching procedure with the R pack-
age MatchIt.17 We first selected matched controls using ran-
dom selection within a calliper width of SD 0.1 on the logit
scale. That is, for each case, we considered the set of controls
whose logit propensity score was within 0.1 SDs of the logit
propensity score of the case and randomly selected two from
the set as the matched controls. If no matches were available
within the calliper, we used the nearest neighbour control to
match the case. In this way, we were able to match all cases
to controls within each stratum.
To assess the association between ICD status and out-
comes by aetiology of HF and to determine whether aetiology
of HF modulated the association between ICD status and
mortality, we constructed Cox proportional hazards models
including ICD, ICM, and their interaction as covariates sepa-
rately for all-cause death, cardiovascular death, and sudden
death. Time zero was defined as the time of randomization
in the survival analyses. Robust variance estimators were
used to adjust for any clustering caused by the matching.
Two-tailed P values < 0.05 were considered statistically sig-
nificant. All analyses were performed using SAS (version 9.4;
SAS Institute, Cary, North Carolina) and R.
Results
Baseline characteristics
The flowchart for the analysis procedure is presented in
Figure 1. Of the 2293 WARCEF participants, 418 had an
ICD at time of enrolment (ICM, N = 223; NICM, N = 195)
Figure 1 Overview of the study cohort. ICD, implantable cardioverter-defibrillator.
Survival benefit of defibrillator in patients with ICM and NICM 299
ESC Heart Failure 2019; 6: 297–307
DOI: 10.1002/ehf2.12407
(Figure 1). Before matching, ICM patients with ICDs were
more likely to be from high-income countries (i.e. excluding
Argentina and Ukraine); younger; have higher education,
lower systolic blood pressure, alcohol consumption, ARB,
lower sodium level; and less likely to have ACE-Inhibitor, as
compared with ICM patients without ICDs. NICM patients with
ICDs were more likely to be from high-income countries, have
lower systolic blood pressure, and have a higher prevalence of
past medical history of atrial fibrillation, have longer distance
on 6 min walk test, and were more likely to take diuretics, as
compared with NICM patients without ICDs (Table 1).
We matched 205 ICM cases to controls and 189 NICM cases
to controls using the calliper criterion and 18 ICM cases to
controls and 6 NICM cases to controls using the nearest
neighbour procedure. The standardized biases of all baseline
covariates were less than 0.25 after matching (Table 2).
Variables with high or moderate missingness include
aldosterone blocker (32%), statin (21%), previous aspirin use
(19%), 6 min walk (7%), and haemoglobin (6%). Missingness
in other variables was negligible. Aldosterone blocker and
6 min walk entered the final propensity score model, with
missing values imputed by mode and mean, respectively.
Primary outcome: All-cause death
Kaplan–Meier curves for all-cause death are presented in
Figure 2. Results from the Cox models are presented in
Table 3. There were 279 deaths in the current analysis (205
deaths among those without ICD and 74 deaths among those
with ICD). For the 585 patients with NICM in the matched co-
hort, a total of 102 (17.4%) died during the follow-up. These
include 31 (15.9%) of the 195 patients with ICDs at baseline
and 71 (18.2%) of the 390matched patients who did not have
ICDs. ICD status did not predict mortality [hazard ratio (HR):
0.984; 95% confidence interval (CI): 0.641 to 1.509;
P = 0.941].
Of the 669 patients with ICM in the matched cohort, 177
(26.5%) died during follow-up. These included 43 (19.3%) of
the 223 patients with ICDs at baseline and 134 (30.0%) of
the 446 matched patients who did not have ICDs. Having an
ICD at baseline was significantly associated with lower mor-
tality (HR: 0.640; 95% CI: 0.448 to 0.915; P = 0.015). There
was a weak evidence of interaction between ICD status and
the aetiology of HF (P = 0.131).
Secondary outcomes: Cardiovascular and sudden
death
Of 279 deaths, a total of 184 (65.9%) were classified as car-
diovascular (133 deaths among patients without ICD and 51
deaths among those with ICD). The relation between ICD sta-
tus and cardiovascular mortality was similar to its relation
with all-cause mortality, though it did not achieve statistical
significance in either subgroups (for ICM, HR: 0.713, 95% CI:
0.473 to 1.075, P = 0.107; for NICM, HR: 0.967, 95% CI:
0.578 to 1.618; P = 0.898; interaction P = 0.365).
A total of 97 deaths were classified as sudden (77 deaths
among those without ICD and 20 deaths among those with
ICD). The association between having ICD and sudden death
was not significant among patients with ICM but was signifi-
cant among patients with NICM (for ICM, HR: 0.673, 95%
CI: 0.385 to 1.176, P = 0.164; patients with NICM, HR:
0.246, 95% CI: 0.077 to 0.781; P = 0.017; interaction
P = 0.124).
Discussion
In this retrospective, propensity-matched analysis of the
WARCEF trial, we found that the presence of ICD at baseline
was associated with a lower risk of all-cause death among
those with ICM but not among those with NICM. There was
weak evidence of an interaction effect for ICD status and
whether a patient had NICM or ICM. These findings are con-
sistent with prior studies showing that the benefit of ICDs is
more pronounced in patients with ICM, but ICDs may be less
effective in patients with NICM.
Our findings are broadly consistent with the recent litera-
ture6,12 suggesting that the effect of ICD may be attenuated
in patients with NICM. Compared with ICM, NICM is known
to be associated with a better left ventricular reverse remod-
elling,18 a better clinical outcome,19 and a lower background
risk for ventricular arrhythmia.20,21 Besides these differences
between ICM and NICM, the evidence for the primary preven-
tion of ICD among patients with NICM is less robust.4–6 The re-
cent DANISH trial, which randomized 1116 patients with NICM
to receive conventional therapy or an ICD, demonstrated no
significant association between the presence of ICD and all-
cause mortality among NICM patients (HR: 0.87; 95% CI:
0.68 to 1.12; P = 0.28). Similarly to the WARCEF population,
the rates of optimal medical therapy in DANISH trial partici-
pants were high. Studies have consistently shown that the op-
timal medical therapies, such as ACE-Inhibitors,22 ARBs,23
beta-blockers,24 mineralocorticoid-receptor antagonists,25 or
combinations of these medications,26 all reduce the rate of
cardiovascular death or sudden death. It is, therefore, possible
that sudden death in medically optimized HF patients may be
less common, leading to diminished benefit from ICDs.
It may be surprising that in our analysis, ICD status pre-
dicted mortality in patients with ICM, but its association on
sudden death was not found to be statistically significant.
Conversely, ICD status did not predict mortality in patients
with NICM in our analysis but did have a strong association
with sudden death. However, these results regarding sudden
death must be interpreted with caution, as the adjudication
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in WARCEF was not blinded to defibrillator status, and the
number of sudden death events was small. In addition, the
DANISH trial6 has shown that in the populations with NICM
in which ICDs did not reduce overall mortality, ICDs may
nonetheless have an apparent effect on sudden death (HR:
0.50; 95% CI: 0.31 to 0.82; P = 0.005).
Despite our findings, there remains uncertainty regarding
the current recommendation for ICD implantation in patients
with NICM. Subsequent analysis of the DANISH trial has
shown that ICD implantation may be beneficial in NICM
patients younger than 70 years of age.27 Compared with
the DANISH trial in which the median age was 63 years old,
NICM patients in the WARCEF trial were considerably youn-
ger, with a median age of 58 years old. It is therefore unclear
if age or other clinical risk predictors might be helpful in guid-
ing decision for ICD implantation in patients with NICM. Fur-
thermore, statistical power remains a concern for both the
DANISH trial and our analysis, as recent meta-analyses con-
tinue to suggest a survival benefit for ICD implantation
among patients with NICM7–11 even after the inclusion of
the DANISH trial. Nonetheless, differences in patient clinical
characteristics and contemporary background medical ther-
apy may affect the validity of these findings, and thereby, fu-
ture studies with carefully defined patient selection criteria
will be needed to clarify whether ICD implantation can be
beneficial in subgroups of patients with NICM.28
Limitations
First, our study was retrospective and therefore necessarily
hypothesis generating. ICD status was not randomly assigned,
which raised the potential for indication bias. To address this,
we used a propensity-matching approach, which can address
confounding from known baseline covariates. However, re-
sidual confounding may still be present, because the decision
to place an ICD is often nuanced and incorporates additional
unmeasured patient clinical and psychosocial characteristics.
Second, past medical history of cardiac arrest was not re-
corded at baseline, and it is possible that a small number of
patients received ICDs for secondary prevention. However,
these patients are more likely to benefit from ICDs,29 which
therefore would not affect our null finding for patients with
NICM. Third, we did not collect detailed information on CRT
status at baseline, or whether patients received ICD and/or
CRT during follow-up. We also did not collect electrocardio-
gram data such as QRS duration or presence of left bundle
branch block. We therefore were not able to control for these
potential confounders. Fourth, WARCEF was limited to pa-
tients in sinus rhythm at baseline, which may limit the exter-
nal validity of our analysis. Fifth, our propensity matching led
to exclusion of more than half of the patients with NICM from
the current analysis, and our findings therefore must be
interpreted cautiously.
Figure 2 Kaplan–Meier curves showing the survival of those with and
without an implantable cardioverter-defibrillator: (A) patients with non-
ischaemic heart failure and (B) patients with ischaemic heart failure.
Table 3 Hazard ratio to assess the effect of ICD status on mortality for those with ICM and with NICM based on the matched sample
Patients with ICM Patients with NICM
Interaction
P valueHazard ratio (95% CI) P value Hazard ratio (95% CI) P value
All-cause death 0.640 (0.448–0.915) 0.015 0.984 (0.641–1.509) 0.941 0.131
Cardiovascular death 0.713 (0.473–1.075) 0.107 0.967 (0.578–1.618) 0.898 0.365
Sudden death 0.673 (0.385–1.176) 0.164 0.246 (0.077–0.781) 0.017 0.124
CI, confidence intervals; ICD, implantable cardioverter-defibrillator; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic
cardiomyopathy.
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Conclusions
In this propensity-matched, retrospective analysis of data
from the WARCEF trial, we found that the presence of ICD
at baseline conveyed a survival benefit in those with ICM
but not in those with NICM. Our results are consistent with
previous literature demonstrating that ICDs are beneficial in
patients with ICM and corroborated the results of the DAN-
ISH trial, which suggested that beneficial effects of ICDs are
attenuated in patients with NICM.
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